CLRB CELLECTAR BIOSCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2026, CELLECTAR BIOSCIENCES INC reported revenue of n/a, net income of −$6.93M and diluted EPS of −$0.57; for the fiscal year ended December 2025 revenue was n/a.
CLRB annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$23.0M, net income −$21.8M (margin n/a), EPS −$8.35
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$51.8M, net income −$44.6M (margin n/a), EPS −$41.89
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$39.0M, net income −$38.0M (margin n/a), EPS −$3.50
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$28.8M, net income −$31.8M (margin n/a), EPS −$4.51
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$24.1M, net income −$24.1M (margin n/a), EPS −$4.35
CLRB quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$6.93M, EPS −$0.57
- Quarter ended Mar 31, 2026: revenue n/a, net income −$5.65M, EPS −$1.33
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$5.30M, EPS $0.75
- Quarter ended Sep 30, 2025: revenue n/a, net income −$4.44M, EPS −$1.41
- Quarter ended Jun 30, 2025: revenue n/a, net income −$5.45M, EPS −$3.39
- Quarter ended Mar 31, 2025: revenue n/a, net income −$6.60M, EPS −$4.30
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$2.36M, EPS −$23.42
- Quarter ended Sep 30, 2024: revenue n/a, net income −$14.7M, EPS −$12.13
- Quarter ended Jun 30, 2024: revenue n/a, net income −$919K, EPS −$5.43
- Quarter ended Mar 31, 2024: revenue n/a, net income −$26.6M, EPS −$0.91
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$3.09M, EPS −$0.41
- Quarter ended Sep 30, 2023: revenue n/a, net income −$17.5M, EPS −$1.55
- Quarter ended Jun 30, 2023: revenue n/a, net income −$10.2M, EPS −$0.90
- Quarter ended Mar 31, 2023: revenue n/a, net income −$7.19M, EPS −$0.64
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$12.4M, EPS −$1.34
- Quarter ended Sep 30, 2022: revenue n/a, net income −$7.51M, EPS −$1.23
- Quarter ended Jun 30, 2022: revenue n/a, net income −$5.64M, EPS −$0.92
- Quarter ended Mar 31, 2022: revenue n/a, net income −$6.24M, EPS −$1.02
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$5.92M, EPS −$2.11
- Quarter ended Sep 30, 2021: revenue n/a, net income −$5.82M, EPS −$0.97
CLRB cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$23.1M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$47.6M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$32.4M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$25.2M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$22.6M, share buybacks n/a
CLRB balance sheet
- Jun 30, 2026: cash $34.0M, total assets $36.6M, total liabilities $6.77M, shareholders' equity $29.9M
- Mar 31, 2026: cash $8.35M, total assets $11.1M, total liabilities $6.40M, shareholders' equity $3.34M
- Dec 31, 2025: cash $13.2M, total assets $15.0M, total liabilities $5.06M, shareholders' equity $8.54M
- Sep 30, 2025: cash $12.6M, total assets $14.6M, total liabilities $5.25M, shareholders' equity $8.00M
- Jun 30, 2025: cash $11.0M, total assets $13.7M, total liabilities $6.23M, shareholders' equity $6.09M
- Mar 31, 2025: cash $13.9M, total assets $16.0M, total liabilities $6.41M, shareholders' equity $8.25M
- Dec 31, 2024: cash $23.3M, total assets $25.5M, total liabilities $9.80M, shareholders' equity $14.3M
- Sep 30, 2024: cash $34.3M, total assets $37.3M, total liabilities $20.7M, shareholders' equity $15.2M
Is CLRB profitable?
No. CELLECTAR BIOSCIENCES INC lost $22.3M over the last four quarters.
What is CLRB's EPS?
Diluted earnings per share over the last four quarters were −$2.56; −$0.57 in the latest quarter.